Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2016
Event: Entry into a Material Definitive Agreement (Securities Purchase Agreement) and related corporate actions.
Key Financial Metrics and Transaction Details
This filing details a private placement financing rather than standard operating financial results. Key transaction metrics include:
- Investor: 10X Fund, L.P.
- Initial Investment: $1,500,000 for 1,500,000 shares of Series B-3 Convertible Preferred Stock (stated value $1.00 per share).
- Initial Closing (Sept 22, 2016): Issuance of 375,000 shares of Series B-3 Preferred Stock and warrants to purchase 104,408 shares of Common Stock.
- Second Closing (Sept 29, 2016): Issuance of remaining 1,125,000 shares of Series B-3 Preferred Stock.
- Future Closings: Option to issue up to 4,500,000 additional shares of Series B-3 Preferred Stock by November 22, 2016.
- Dividend Rate: 8% per annum (compounding monthly), payable in cash or stock; accrues at 15% if unpaid.
- Warrant Exercise Price: $3.00 per share (subject to adjustments).
Material Changes and Corporate Actions
The filing reports several material changes to the company's capital structure and governance:
- New Security Series: Establishment of Series B-3 Convertible Preferred Stock with specific conversion and dividend terms.
- Lock-Up Agreement: The investor agreed to an 18-month lock-up period on shares acquired. In consideration, the Company issued "Lock-Up Warrants" to purchase up to 2,000,000 shares of Common Stock in the aggregate.
- Registration Rights: Agreement to register for resale the Common Stock underlying the Series B-3 Preferred Stock and associated warrants.
- Bylaw Amendment: Directors will now be elected by a plurality of votes cast by holders of capital stock present and entitled to vote.
- Certificate of Designation: Filed to remove the ability of Series B Preferred Stock to cause a redemption and to add Series B-3 terms.
Outlook, Risks, and Unusual Items
- Future Financing: The Company expects any subsequent closings under the Purchase Agreement to occur on or before November 22, 2016, though this date may be extended.
- Clinical Trial Update: On September 27, 2016, the Company issued a press release regarding results from its NASH-FX clinical trial (referenced in Item 8.01).
- Conversion Mechanics: The conversion price for the Series B-3 Preferred Stock is based on the closing price of Common Stock prior to issuance plus $0.09375, creating potential dilution dependent on market price.
- Unregistered Sales: Securities were issued in reliance on Section 4(2) of the Securities Act and Rule 506 of Regulation D, meaning they are "restricted securities."
Investor Verification Checklist
- Verify the closing price of Common Stock on September 28, 2016, to calculate the exact conversion price and warrant count for the September 29 closing.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and closing conditions.
- Examine the press release (Exhibit 99.1) for details on the NASH-FX clinical trial results and their impact on the business outlook.
- Confirm the total dilution impact of the Series B-3 Preferred Stock, Series B-3 Warrants, and Lock-Up Warrants on existing shareholders.
- Check the status of the registration statement required under the Registration Rights Agreement.